Is medical cannabis legal in Mexico?

Yes. The Ley General de Salud was amended in 2017 to permit medical cannabis. The implementing reglamento was published January 12, 2021. The program runs through COFEPRIS-authorized pharmacies and is pharmaceutical-preparation only — flower is excluded.

How many medical cannabis patients are there in Mexico?

Fewer than 5,000 active patients as of 2024–2025, by industry-association estimates. This is a tiny figure relative to Germany (hundreds of thousands pre-2024), Canada (~300,000 at peak), or any U.S. state medical program.

Can I smoke medical cannabis in Mexico?

No. The 2021 reglamento excludes cannabis flower from the medical pathway. Authorized products are pharmaceutical preparations — oils, capsules, isolates, sprays — distributed through pharmacies.

Mexico Medical Cannabis Program — A Tiny Pharmacy Channel

Q: Does Mexico recognize US medical cannabis cards?

No. Mexico does not recognize U.S. state medical cannabis cards or any foreign cannabis prescription. Mexican pharmacies cannot honor foreign prescriptions for cannabis. Foreign patients cannot legally bring their cannabis products into Mexico.

Medical Disclaimer: This information is educational only and does not constitute medical advice. Cannabis affects everyone differently. Always consult a qualified healthcare provider before using cannabis, especially if you take other medications.

Last verified: April 2026

Mexico's Medical Cannabis Program at a Glance

Mexico's medical cannabis program is, in international comparison, vanishingly small. Estimates aggregated from COFEPRIS reporting, industry associations such as AsoCann, and reporting in Forbes México place the figure at fewer than 5,000 active patients as of 2024–2025. By comparison, Germany's medical program (with a smaller population) crossed several hundred thousand patients well before its 2024 broader reform; Canada's hit roughly 300,000 at its peak.

Key Facts

Legal Status	Legal under 2017 Ley General de Salud reform; implementing reglamento January 2021
Regulator	COFEPRIS under the Secretaría de Salud
Distribution Channel	Pharmacies only — Farmacias del Ahorro, Similares, Guadalajara, others
Authorized Products	Pharmaceutical preparations: oils, capsules, isolates, sprays
Excluded	Flower (smokable cannabis) — not authorized through the medical pathway
Active Patients	Fewer than 5,000 (as of 2024–2025)
Insurance Coverage	IMSS and ISSSTE generally do not cover; private insurance rare
Visitor Reciprocity	None — Mexico does not recognize foreign medical cannabis cards

The 2017 Reform Under Peña Nieto

Mexico took its first formal step toward medical cannabis on June 19, 2017, when President Enrique Peña Nieto signed into law a reform of the Ley General de Salud authorizing the medical and scientific use of cannabis and its pharmacological derivatives. The reform was championed by Grace Olivier de Bonilla and the family of Graciela Elizalde ("Grace") — a young girl with Lennox-Gastaut Syndrome whose family won an amparo in 2015 to import CBD oil.

The 2017 reform modified Articles 235, 237, 245, 247, and 290 of the LGS. It reclassified products containing less than 1% THC out of Group I (most restrictive), opening a path for pharmaceutical CBD. It directed the Secretaría de Salud to issue regulations.

The 2021 Reglamento

Implementing regulations took three and a half years. On January 12, 2021, the federal government published the Reglamento de la Ley General de Salud en Materia de Control Sanitario para la Producción, Investigación y Uso Medicinal de la Cannabis y sus Derivados Farmacológicos in the Diario Oficial de la Federación. The reglamento is COFEPRIS-administered and governs:

Authorizations for research (university and clinical)
Authorizations for cultivation for medical purposes
Authorizations for production of pharmaceutical derivatives
Importation of finished products
Pharmacy distribution as the only retail channel

Why No Flower?

Notably, the reglamento excludes flower from medical authorization. Patients cannot obtain or smoke cannabis flower through the medical pathway. Authorized products must be pharmaceutical preparations — oils, capsules, isolates, sprays — meeting Mexican Norma standards.

This is a significant constraint compared to Canada, Germany, and most U.S. medical programs, where flower is a primary product. The Mexican framework reflects the public-health framing favored by the Secretaría de Salud and the absence of a domestic cultivation industry geared toward smokable medical product.

Who Administers and Enforces

COFEPRIS — registers products, authorizes pharmacies, and oversees production licenses.
Secretaría de Salud — sets policy and Norma standards.
Pharmacy chains — Farmacias del Ahorro, Similares, Guadalajara, San Pablo, and Benavides distribute.
Physicians — any Mexican physician with a valid cédula profesional can prescribe within the framework.

For Foreign Visitors and Patients

No Cross-Border Medical Reciprocity

Mexico does not recognize U.S. state medical cannabis cards, Canadian Health Canada medical authorizations, or any foreign medical-cannabis prescription. Foreign patients cannot legally bring their cannabis products into Mexico, and Mexican pharmacies cannot honor foreign prescriptions for cannabis. See full reciprocity guide.

Explore the Medical Program

Eligible Conditions

Refractory epilepsy, MS, neuropathic pain, cancer-related symptoms, and others.

Products & Pharmacies

Epidiolex, Sativex, COFEPRIS-registered CBD oils — where to buy.

Cost & Access

Why fewer than 5,000 patients use the program.

Visitor Reciprocity

U.S. state cards do not work in Mexico. The reasons.

Official Sources

COFEPRIS — Cannabis medicinal
Diario Oficial de la Federación — reglamento full text
Secretaría de Salud